TVTX FY 2024 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$233M+60.5% YoY

Gross Profit

$225M96.7% margin

Operating Income

-$324M-138.9% margin

Net Income

-$322M-137.9% margin

EPS (Diluted)

$-4.08

Cash Flow

Operating Cash Flow

-$237M

Free Cash Flow

-$339M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$594M

Total Liabilities

$535M

Stockholders' Equity

$59M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$233M	$145M	+60.5%
Gross Profit	$225M	$134M	+68.5%
Operating Income	-$324M	-$388M	+16.6%
Net Income	-$322M	-$111M	-188.6%